IDRI research lays emphasis on identifying new therapies to fight tuberculosis (TB), including multidrug-resistant TB (MDR-TB).
The additional funding through Eli Lilly to support early stage TB drug discovery efforts through IDRI brings the total amount to $20m.
Eli Lilly and Company senior research fellow Philip Hipskind said they have made strong links with IDRI and intend to bolster the drug discovery capabilities of each organization.